ASCO 2023 | NeoALTTO: HER2/CEP17 ratio as a predictive biomarker in HER+ breast cancer

Michael Gnant, MD, FACS, FEBS, Medical University of Vienna, Vienna, Austria, discusses findings from the Phase III NeoALTTO trial (NCT00553358), which compared a neoadjuvant tyrosine kinase inhibitor with immunotherapy in patients with HER2-positive breast cancer. The link between the HER2/CEP17 ratio and efficacy of neoadjuvant therapy was additionally assessed. The HER2/CEP17 ratio was able to predict pathological complete response, hence identify patients who may benefit from this form of treatment. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.